HCTZ

Hydrochlorothiazide is a small-molecule drug of the thiazide class of diuretics, agents that promote the loss of salt and water through the kidneys ^[1]. First made commercially available in 1959, it has stayed a cornerstone of blood-pressure management for more than six decades and ranks among the most frequently dispensed medicines in many countries ^[1][2]. It is taken by mouth and is available in inexpensive generic form.

Its principal use is in the treatment of hypertension, either on its own or, more often, combined with other antihypertensive drugs in fixed-dose products ^[1]. It is also used to reduce edema, the swelling caused by fluid accumulation in conditions such as heart failure, and it carries more specialized roles, among them lowering urinary calcium to help prevent certain kidney stones and managing some forms of diabetes insipidus ^[1][4]. Large evidence syntheses have found that low-dose thiazide therapy used as a first-line treatment reduces death, stroke, and other cardiovascular events in people with moderate to severe hypertension ^[2].

Pharmacologically, hydrochlorothiazide acts on a specific salt-handling protein in the kidney tubule to limit sodium reabsorption, which in turn draws water into the urine ^[1]. Because it shifts the body's balance of electrolytes, it can lower potassium while raising calcium and uric acid, effects that shape both its therapeutic use and its side effects ^[1][4].

The drug is generally well tolerated but carries recognized risks. Common concerns include low blood potassium and other electrolyte disturbances, elevated blood sugar and lipids, raised uric acid that can provoke gout, and photosensitivity of the skin ^[1][4]. Long-term, high cumulative use has been linked in epidemiological studies to an increased risk of non-melanoma skin cancers, particularly squamous cell carcinoma, an association attributed in part to the drug's photosensitizing property ^[3]. International cancer authorities have since reviewed and classified the compound with respect to this risk ^[3].

Hydrochlorothiazide is a prescription medicine worldwide and is listed by the World Health Organization as an essential medicine ^[1]. It is supplied as oral tablets and capsules, both as a single agent and in numerous combination formulations paired with drugs such as angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, and potassium-sparing diuretics ^[1][2].

Hydrochlorothiazide is a thiazide diuretic whose main risks are electrolyte disturbances, especially low potassium, sodium, and magnesium and elevated calcium, along with dehydration and low blood pressure. It can raise blood glucose, uric acid (precipitating gout), and lipids, cause photosensitivity, and long-term use has been associated with an increased risk of non-melanoma skin cancer. Electrolytes should be monitored, and it should be used cautiously in those with sulfonamide sensitivity.

Hydrochlorothiazide increases serum lithium concentrations through a pharmacokinetic mechanism by reducing renal lithium clearance, leading to lithium toxicity ^[21]. Thiazide diuretics produce the largest effect among diuretic classes, typically increasing lithium levels by 25 to 40 percent after initiation ^[21]. Case reports demonstrate that HCTZ combined with other antihypertensives like valsartan can precipitate symptomatic lithium toxicity including parkinsonism and severe hypothyroidism in elderly patients ^[22]; animal models show HCTZ accelerates progression of lithium-induced nephropathy and renal failure ^[23]. NSAIDs, ACE inhibitors, and other medications that affect renal function may potentiate this interaction. No systematic study of HCTZ with non-lithium mood stabilizers or other psychiatric medications has established clinically relevant interactions.

Checking a whole stack? Run it through interactions + stacks.

Hydrochlorothiazide belongs to the thiazide class of diuretics, whose discovery grew out of mid-twentieth-century research on sulfonamide carbonic anhydrase inhibitors at Merck, where Karl Beyer and colleagues developed chlorothiazide, introduced in 1958. Hydrochlorothiazide followed almost immediately as a more potent derivative and reached the market around 1959, sold under names such as Esidrix and HydroDIURIL. The thiazides quickly transformed the management of hypertension and edema, offering effective oral blood-pressure control at a time when options were scarce. Over the following decades hydrochlorothiazide became one of the most widely prescribed antihypertensive agents in the world and earned a place on the World Health Organization's List of Essential Medicines. It remains a foundational drug in cardiovascular medicine more than sixty years after its introduction.

Hydrochlorothiazide is one of the most enduring and widely trusted medicines in cardiovascular care, a low-cost oral drug that has helped control blood pressure for generations of patients. Its mechanism is well understood: by inhibiting the sodium-chloride cotransporter in the distal tubule it increases sodium and water excretion, reducing blood volume and, over time, arterial pressure. Decades of clinical use and inclusion on the WHO essential medicines list attest to its value, and it is frequently combined with other agents in fixed-dose antihypertensive tablets.

A useful secondary property is that it reduces urinary calcium, which makes it helpful in preventing calcium-containing kidney stones. Honesty calls for noting its predictable metabolic effects, including potassium loss, and raised uric acid, glucose, and lipids, which require monitoring; even so, its affordability, simplicity, and long safety record keep it a first-line staple worldwide.